Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

PaperCitations, authors & open-access status

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 741 citations, 2021 year and hybrid oa status.

741
Citations
2021
Year
hybrid
OA Status

Related on ScholarIQ

Yan Wang
Author
Joyce O’Shaughnessy
Author
James Chih‐Hsin Yang
Author
Annals of Oncology
Journal
Cancer Immunotherapy and Biomarkers
Topic
Cancer Immunotherapy and Biomarkers
Topic
470M+ articles · free account